New AbbVie Subpopulation Data May Provide Edge Over Gilead In HCV Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma may seek labeling update for 12 weeks of ribavirin-free therapy in genotype 1 patients with cirrhosis; Gilead’s label calls for 24 weeks of therapy.